17 July 2017

Amedeo Smart

Independent Medical Education

Subscriber: th..@boehringer-ingelheim.com

HIV Infection

17 July 2017 | n=52

  1. Saris J, van den Berk G, Moha DA, van der Meer J, et al.
    Successful implementation of hepatitis C virus treatment in two large HIV clinics in Amsterdam: hepatitis C virus treatment cascade of care.
    AIDS 2017;31:1779-1780.

  2. Smit DP, Meyer D.
    HIV-induced uveitis: would you recognize it if it looked straight at you?
    AIDS 2017;31:1777-1779.

  3. Kheloufi F, Boucherie Q, Blin O, Micallef J, et al.
    Neuropsychiatric events and dolutegravir in HIV patients: a worldwide issue involving a class effect.
    AIDS 2017;31:1775-1777.

  4. Lal L, Audsley J, Murphy DA, Fairley CK, et al.
    Medication adherence, condom use and sexually transmitted infections in Australian preexposure prophylaxis users.
    AIDS 2017;31:1709-1714.

  5. Youn B, Shireman TI, Lee Y, Galarraga O, et al.
    Ten-year trends in antiretroviral therapy persistence among US Medicaid beneficiaries.
    AIDS 2017;31:1697-1707.

  6. Caby F.
    CD4+/CD8+ ratio restoration in long-term treated HIV-1-infected individuals.
    AIDS 2017;31:1685-1695.

  7. Zeng H, Wang L, Liu P, Liao L, et al.
    Seroprevalence of hepatitis E virus in HIV-infected patients in China.
    AIDS 2017.

  8. Philibert P, Chiche L, Cailleres S, Allemand J, et al.
    HHV8 and Kaposi's sarcoma: should we really give up protease inhibitors in all HIV-infected patients?
    AIDS 2017.

  9. Van Zummeren M, Kremer WW, Van Aardt MC, Breytenbach E, et al.
    Selection of women at risk for cervical cancer in an HIV-infected SOUTH AFRICAN population.
    AIDS 2017.

  10. Stoner MCD, Pettifor A, Edwards JK, Aiello AE, et al.
    The effect of school attendance and school dropout on incident HIV and HSV-2 among young women in rural South Africa enrolled in HPTN 068.
    AIDS 2017.

  11. McBain RK, Petersen E, Tophof N, Dunbar E, et al.
    Impact and economic evaluation of a novel HIV service delivery model in rural Malawi.
    AIDS 2017.

  12. Donnell D, Ramos E, Celum C, Baeten J, et al.
    The Effect of Oral Pre-Exposure Prophylaxis on the Progression of HIV-1 Seroconversion.
    AIDS 2017.

  13. Hyle EP, Jani IV, Rosettie KL, Wood R, et al.
    The value of point-of-Care CD4 and Laboratory viral Load in tailoring ART monitoring Strategies to resource limitations.
    AIDS 2017.

  14. Fulcher JA, Koukos G, Koutsioumpa M, Elliott J, et al.
    Unique microRNA Expression in the Colonic Mucosa During Chronic HIV-1 Infection.
    AIDS 2017.

  15. Singh KP, Crane M, Audsley J, Lewin SR, et al.
    HIV-hepatitis B virus co-infection: epidemiology, pathogenesis, and treatment.
    AIDS 2017.

  16. Lemoine M, Lacombe K, Bastard JP, Sebire M, et al.
    Metabolic syndrome and obesity are the cornerstones of liver fibrosis in HIV-monoinfected patients: results of the METAFIB study.
    AIDS 2017.

  17. Hong JJ, Silveira ELV, Amancha PK, Byrareddy SN, et al.
    Early initiation of antiretroviral treatment post SIV infection does not resolve lymphoid tissue activation.
    AIDS 2017.

  18. Vieira VA, Avelino-Silva VI, Cerqueira NB, Costa DA, et al.
    Asymptomatic anorectal Chlamydia trachomatis and Neisseria gonorrhoeae infections are associated with systemic CD8+ T cell activation.
    AIDS 2017.

  19. Gianella S, Chaillon A, Mutlu EA, Engen PA, et al.
    Effect of CMV and EBV replication on intestinal mucosal gene expression and microbiome composition of HIV-infected and uninfected individuals.
    AIDS 2017.

  20. Sun B, Dalvi P, Abadjian L, Tang N, et al.
    Blood neuron-derived exosomes as biomarkers of cognitive impairment in HIV.
    AIDS 2017.

  21. Elzi L, Erb S, Furrer H, Cavassini M, et al.
    Adverse events of raltegravir and dolutegravir: a prospective analysis of 4,041 HIV-infected individuals from the Swiss HIV Cohort Study.
    AIDS 2017.

  22. Lafleur J, Bress AP, Rosenblatt L, Crook J, et al.
    Cardiovascular outcomes among HIV-infected veterans receiving atazanavir: a US national historical cohort study.
    AIDS 2017.

  23. Chappell CA, Lamorde M, Nakalema S, Chen B, et al.
    Efavirenz decreases etonogestrel exposure: a pharmacokinetic evaluation of implantable contraception with antiretroviral therapy.
    AIDS 2017.

  24. Vanhommerig JW, Bezemer D, Molenkamp R, Van Sighem AI, et al.
    Limited overlap between phylogenetic HIV and HCV clusters illustrates the dynamic sexual network structure of Dutch HIV-infected MSM.
    AIDS 2017.

  25. Gross R, Bellamy SL, Ratshaa B, Han X, et al.
    CYP2B6 genotypes and early efavirenz-based hiv treatment outcomes in botswana.
    AIDS 2017.

  26. Rose RR, Nolan DJ, Maidji E, Stoddart C, et al.
    Eradication of HIV from Tissue Reservoirs: Challenges for the Cure.
    AIDS Res Hum Retroviruses 2017.

  27. .
    Conception Without HIV Transmission.
    JAMA 2017;318:117.

  28. Chikwari CD, Ferrand RA, Simms V.
    Association between self-reported adherence and HIV viral load suppression among older children and adolescents.
    J Acquir Immune Defic Syndr 2017.

  29. Rolle CP, Rosenberg ES, Siegler AJ, Sanchez TH, et al.
    Challenges in Translating PrEP Interest into Uptake in an Observational Study of Young Black MSM.
    J Acquir Immune Defic Syndr 2017.

  30. Calcagno A, Piconi S, Foca E, Nozza S, et al.
    Role of Normalized T-Cell Subsets in Predicting Comorbidities in a Large Cohort of Geriatric HIV-infected Patient.
    J Acquir Immune Defic Syndr 2017.

  31. Chen M, Dou Z, Wang L, Wu Y, et al.
    Gender differences in outcomes of antiretroviral treatment among HIV-infected patients in China: a retrospective cohort study, 2010-2015.
    J Acquir Immune Defic Syndr 2017.

  32. Jiamsakul A, Kariminia A, Althoff KN, Cesar C, et al.
    HIV viral load suppression in adults and children receiving antiretroviral therapy - results from the IeDEA collaboration.
    J Acquir Immune Defic Syndr 2017.

  33. Johnson AS, Song R, Hall HI.
    Estimated HIV incidence, prevalence, and undiagnosed infections in US states and Washington, DC, 2010-2014.
    J Acquir Immune Defic Syndr 2017.

  34. Blitz S, Antoniou T, Burchell A, Walmsley S, et al.
    The use of multistate models to examine associations of stress and adherence with transitions among HIV care states observed in a clinical HIV cohort.
    J Acquir Immune Defic Syndr 2017.

  35. Manne-Goehler J, Montana L, Gomez-Olive FX, Rohr J, et al.
    The ART Advantage: Health Care Utilization for Diabetes and Hypertension in Rural South Africa.
    J Acquir Immune Defic Syndr 2017;75:561-567.

  36. Mayer KH, Jones D, Oldenburg C, Jain S, et al.
    Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.
    J Acquir Immune Defic Syndr 2017;75:535-539.

  37. Taylor BS, So-Armah K, Tate JP, Marconi VC, et al.
    HIV and Obesity Comorbidity Increase Interleukin 6 but Not Soluble CD14 or D-Dimer.
    J Acquir Immune Defic Syndr 2017;75:500-508.

  38. Henriquez JE, Rizzo MD, Schulz MA, Crawford RB, et al.
    Delta9-Tetrahydrocannabinol Suppresses Secretion of IFNalpha by Plasmacytoid Dendritic Cells From Healthy and HIV-Infected Individuals.
    J Acquir Immune Defic Syndr 2017;75:588-596.

  39. Yen YF, Jen IA, Chen M, Lan YC, et al.
    HIV Infection Increases the Risk of Incident Psoriasis: A Nationwide Population-Based Cohort Study in Taiwan.
    J Acquir Immune Defic Syndr 2017;75:493-499.

  40. Wehmeyer MH, Ingiliz P, Christensen S, Hueppe D, et al.
    Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: results from the multicenter German hepatitis C cohort (GECCO-03).
    J Med Virol 2017.

  41. Lisboa Neto G, M Malta F, Gomes-Gouvea MS, F Noble C, et al.
    J Med Virol 2017.

  42. Marra E, King A, van Logchem E, van der Weele P, et al.
    Anal HPV 16 and 18 viral load: a comparison between HIV-negative and HIV-positive MSM and association with persistence.
    J Med Virol 2017.

  43. Wang K, Tomaras GD, Jegaskanda S, Moody MA, et al.
    Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate ADCC, and Protect Mice from Ocular Challenge with HSV-1
    J Virol 2017.

  44. Bogers WMJM, Barnett SW, Oostermeijer H, Nieuwenhuis IG, et al.
    Increased, durable B-cell and ADCC Responses Associated with T-helper Responses to HIV-1 Envelope in Macaques Vaccinated with gp140 Occluded at the CD4 Receptor Binding Site.
    J Virol 2017.

  45. Desrosiers RC.
    Protection against HIV Acquisition in the RV144 Trial.
    J Virol 2017.

  46. Bauer A, Podola L, Mann P, Missanga M, et al.
    Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA prime - Modified Vaccinia Ankara (MVA) boost HIV-1 vaccine regimen.
    J Virol 2017.

  47. Madhavi V, Wines BD, Amin J, Emery S, et al.
    HIV-1 Env- and Vpu-specific antibody-dependent cellular cytotoxicity responses associated with elite control of HIV.
    J Virol 2017.

  48. Fujino M, Sato H, Okamura T, Uda A, et al.
    Simian Immunodeficiency Virus Targeting of CXCR3+ CD4+ T Cells in Secondary Lymphoid Organs Is Associated with Robust CXCL10 Expression in Monocyte/Macrophage Subsets.
    J Virol 2017;91.

  49. Garvie PA, Brummel SS, Allison SM, Malee KM, et al.
    Roles of Medication Responsibility, Executive and Adaptive Functioning in Adherence for Children and Adolescents With Perinatally Acquired HIV.
    Pediatr Infect Dis J 2017;36:751-757.

  50. Medley GF, Vassall A.
    When an emerging disease becomes endemic.
    Science 2017;357:156-158.

  51. Desimio MG, Giuliani E, Doria M.
    The histone deacetylase inhibitor SAHA simultaneously reactivates HIV-1 from latency and up-regulates NKG2D ligands sensitizing for natural killer cell cytotoxicity.
    Virology 2017;510:9-21.

  52. Das S, Boliar S, Samal S, Ahmed S, et al.
    Identification and characterization of a naturally occurring, efficiently cleaved, membrane-bound, clade A HIV-1 Env, suitable for immunogen design, with properties comparable to membrane-bound BG505.
    Virology 2017;510:22-28.

Display articles in

Amedeo HIV Infection

Data Origin

You selected the following journals for your Amedeo HIV Infection newsletter:

AIDS, AIDS Res Hum Retroviruses, Ann Intern Med, BMJ, Clin Infect Dis, J Acquir Immune Defic Syndr, J Clin Immunol, J Clin Invest, J Infect Dis, J Med Virol, J Virol, JAMA, Lancet, N Engl J Med, Nat Med, Pediatr Infect Dis J, Science, Virology.

To modify the journal selection, please open your Newsletter Management Page. If you don't remember the URL, please submit the email address of your Amedeo subscription.

Your email:

Amedeo HIV Infection

Five-Week Literature

16 July 2018

09 July 2018

02 July 2018

25 June 2018

18 June 2018

17 July 2017

Multidisciplinary Journal Club

  1. Donohue MC, Sperling RA, Petersen R, Sun CK, et al.
    Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons.
    JAMA. 2017;317:2305-2316.

  2. Feinberg J, Keeshin S.
    Management of Newly Diagnosed HIV Infection.
    Ann Intern Med. 2017;167:ITC1-ITC16.

  3. Mancio-Silva L, Slavic K, Grilo Ruivo MT, Grosso AR, et al.
    Nutrient sensing modulates malaria parasite virulence.
    Nature. 2017 Jul 5. doi: 10.1038/nature23009.

Every week, Amedeo's Multidisciplinary Journal Club (MJC) presents a selection of outstanding articles. Take a look beyond the horizon.

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016